BeiGene, Ltd. Share Price

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 22/04/2024 BST 5-day change 1st Jan Change
130.9 USD +1.10% Intraday chart for BeiGene, Ltd. -5.39% -27.40%
Sales 2024 * 3.08B 249B Sales 2025 * 3.93B 318B Capitalization 13.53B 1,096B
Net income 2024 * -892M -72.22B Net income 2025 * -358M -28.99B EV / Sales 2024 * 3.91 x
Net cash position 2024 * 1.48B 120B Net cash position 2025 * 1.13B 91.56B EV / Sales 2025 * 3.16 x
P/E ratio 2024 *
-15.2 x
P/E ratio 2025 *
-40 x
Employees 10,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.10%
1 week-5.39%
Current month-16.27%
1 month-13.87%
3 months-16.40%
6 months-22.40%
Current year-27.40%
More quotes
1 week
126.97
Extreme 126.9681
137.71
1 month
126.97
Extreme 126.9681
159.34
Current year
126.97
Extreme 126.9681
184.80
1 year
126.97
Extreme 126.9681
266.67
3 years
118.18
Extreme 118.18
426.56
5 years
113.01
Extreme 113.01
426.56
10 years
22.51
Extreme 22.51
426.56
More quotes
Date Price Change Volume
22/04/24 130.9 +1.10% 149 705
19/04/24 129.5 -1.85% 296,412
18/04/24 132 +0.08% 125,955
17/04/24 131.9 -1.63% 200,058
16/04/24 134 -3.14% 308,982

Delayed Quote Nasdaq, April 22, 2024 at 09:00 pm

More quotes
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
129.5 USD
Average target price
268.6 USD
Spread / Average Target
+107.41%
Consensus